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Objectives: This manuscript describes the development, validation and clinical application of a novel method for
the quantification of the antiretroviral drug efavirenz in dried breast milk spots using LC-MS.
Methods: Dried breast milk spots were prepared by spotting 30 mL of human breast milk on each circle of
Whatman 903 Protein Saver cards. Chromatographic separation was achieved on a reverse-phase C18 column
with 1 mM ammonium acetate in water/acetonitrile using a solvent gradient at a flow rate of 400 mL/min and
detection was by TSQ Quantum Access triple quadrupole mass spectrometer equipped with a heated electro-
spray ionization source. The method was applied to characterize the breast milk pharmacokinetic profile of efa-
virenz in HIV-positive nursing mothers receiving regimens containing 600 mg of efavirenz once daily.
Results: The assay was validated over the concentration range 50–7500 ng/mL. Accuracy ranged between
95.2% and 102.5% and precision ranged between 1.05% and 9.53%. The average recovery of efavirenz from
dried breast milk spots was 106.4% and the matrix effect was 8.14%. Stability of efavirenz in dried breast milk
spots and processed samples at room temperature, 2408C and 2808C was demonstrated. In the pharmacoki-
netic study, the mean (SD) AUC0–24, Cmax and Cmin of efavirenz in breast milk were 59620 ng.h/mL (17440),
4527 ng/mL (1767) and 1261 ng/mL (755.9), respectively. The mean (range) milk-to-plasma concentration
ratio over the dosing interval was 0.78 (0.57–1.26).
Conclusions: The dried breast milk spot method is simple, robust, accurate and precise, and can be used in set-
tings with limited resources.
Keywords: liquid chromatography, mass spectrometry, antiretroviral
Introduction
The WHO recommends exclusive, ‘on demand’ breastfeeding
starting within 1 h of birth, up to 6 months of age, and continued
with gradual introduction of appropriate complementary foods up
to 2 years of age or beyond. In addition to its nutritional benefits,
ready availability and affordability, the health benefits of breast-
feeding for both infant andmother have long been recognized.1–4
However, breastfeeding in the presence of maternal drug use is
widespread despite the lack of safety data for either proscriptions
or permissive statements. In fact, over 90% of nursing mothers
take at least one drug during the first week after delivery, 17%
take at least one drug until 4 months after delivery and 5% receive
drugs for chronic conditions, giving rise to concerns over the
presence of drugs in breast milk and their potential effects on
the nursing infant.5
Making an informed decision requires an accurate evaluation of
the potential risks versus benefits based on knowledge of the
extent of the drug’s excretion in human breast milk.6 For instance,
HIV-positivemothers breastfeed their babieswhile taking antiretro-
viral drugs (ARVs) started during pregnancy for their own health
and for prevention of mother-to-child transmission (PMTCT) of
HIV. Understanding the dynamics of HIV viral load in breast milk
and the safety of maternal drugs for the breastfed infant requires
understanding of the pharmacokinetics of ARVs in breast milk.7
Therapeutic drug concentrations in breastmilk can prevent ongoing
localized replication of viral reservoir and the development of
drug-resistant virus,8 which may otherwise be passed to infants,
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who become infected if PMTCT fails.9 On the other hand, high con-
centrations may lead to toxicity in exposed infants.
Very few bioanalytical methods have been described in the lit-
erature for the quantification of ARVdrugs in breastmilk. The com-
plexity of breast milk makes available methods either difficult to
validate because of inadequate sample clean-up or complicated
due to multiple sample clean-up steps involving a combination of
liquid–liquid and solid-phase extraction in a singlemethod.10,11 In
addition, lack of standardization makes cross-study comparisons
difficult, particularly given differential drug accumulation within
specific fractions of milk. For instance, studies reporting the excre-
tion of abacavir, efavirenz, etravirine, lamivudine, lopinavir, nevir-
apine, zidovudine, tenofovir and emtricitabine in human breast
milk have used methods validated only in plasma.12–17 A fully
validated method was described for the quantification of lamivu-
dine, lopinavir, nelfinavir, nevirapine, ritonavir, stavudine and
zidovudine (7 out of 25 ARVs in use) in breast milk.18 However,
the multiple extraction steps make the method time-consuming
and expensive, which is a barrier to implementation in resource-
limited settings. No fully validatedmethod has been described for
the quantification of other ARVdrugs in breast milk, including efa-
virenz, an HIV NNRTI, which is recommended by the WHO as a
regular component of first-line regimens across different
populations.19
The use of dried matrix spots in the bioanalysis of drugs is
increasingly becoming acceptable. This approach is characterized
by several advantages compared with the traditional methods:
low sample volume, ease of collection, biosafety, room-temperature
storage, low-cost shipping, enhanced stability of some analytes20
and the potential for application in intensive pharmacokinetic
studies in special populations. This technique has been described
for whole blood21 and transparent matrices such as plasma,22
CSF,20 urine23 and synovial fluid.24 However, drug quantification
in dried breast milk spots has not been reported. Here we describe
a novel and simple method for the quantification of efavirenz in
total (unfractionated) breast milk extracted from dried filter
paper using LC-MS. Using this method, we describe for the first
time the pharmacokinetics of efavirenz in human breast milk
over a full dosing interval.
Materials and methods
Reference standard of efavirenz was obtained from Toronto Research
Chemicals Inc. (North York, Ontario, Canada) and hexobarbital, used as
an internal standard, was obtained from Sigma-Aldrich (Gillingham,
Dorset, UK). LC-MS-grade acetonitrile was obtained from Fisher
Scientific (Loughborough, Leicestershire, UK) and methanol from VWR
International (Lutterworth, Leicestershire, UK). Water was produced
from an Elga Option 4 water purifier (Elga Labwater, High Wycombe,
Buckinghamshire, UK) and was further purified to 18.2 MV with a
Purelab Classic UVF (Elga LabWater, High Wycombe, Buckinghamshire,
UK). Whatman 903 Protein Saver cards were obtained from Scientific
Laboratory Supplies (Hessle, East Yorkshire, UK). Blank breast milk samples
were obtained (with ethics approval) from Wirral Mothers’ Milk Bank,
Clatterbridge Hospital, Wirral, UK and whole blood was obtained from
drug-free healthy volunteers.
LC-MS/MS systems
The LC system consisted of a variable loop Accela autosampler and an
Accela LC-Pump (Thermo Electron Corporation, Hemel Hempstead,
Hertfordshire, UK). A reverse-phase FortisTM C18 column: 3 mm,
100 mm×2.1 mm (Fortis Technologies Ltd, Neston, Cheshire, UK) was
used to resolve analytes, using a 2 mm C18 Quest column-saver
(Thermo Electron Corporation, Hemel Hempstead, Hertfordshire, UK) as
a guard column. The HPLCwas connected to a TSQ Quantum Access triple
quadrupole mass spectrometer (Thermo Electron Corporation, Hemel
Hempstead, Hertfordshire, UK) equipped with a heated electrospray ion-
ization source. TSQ tune software (Thermo Electron Corporation, Hemel
Hempstead, Hertfordshire, UK) enabled the optimization of tuning para-
meters while LC Quan software (Thermo Electron Corporation, Hemel
Hempstead, Hertfordshire, UK) was used for data acquisition and
processing.
LC-MS/MS conditions
Chromatographic separation was achieved using a solvent gradient pro-
gramme at a flow rate of 400 mL/min. The two mobile phases consisted
of 1 mM ammonium acetate in water (mobile phase A) and 1 mM
ammonium acetate in acetonitrile (mobile phase B). The gradient
started with 70% mobile phase A, decreasing to 10% over 3 min. This
was maintained for 1 min, followed by column equilibration to the
initial conditions over 2 min. The total run time was 5 min. Injection
volume was 10 mL and the needle was washed twice with 3 mL of
methanol/water (1:1, v/v) between injections. The mass spectrometer
was operated in negative ionization mode to produce characteristic frag-
mentation patterns and precursor ions ([M2H]2) for efavirenz and
internal standard, which were then monitored by selective reaction
monitoring.
The electrospray voltagewas set at 3.0 kV, the capillary temperature at
2708C and vaporizer temperature at 3508C. The sheath and auxiliary gas
pressures were set to 60 and 15 arbitrary units, respectively. Argon was
used as the collision gas at a pressure of 1.5 mTorr. Product ion character-
ization was done by directly infusing 1 mg/mL solutions of efavirenz and
hexobarbital separately into the MS using a syringe at a flow rate of
5 mL/min. The transitions were m/z 313.979241.991 and 244.025 for
efavirenz and 235.07142.449 for hexobarbital with optimal collision
energies of 20 and 19 and tube lenses of 76 and 84, respectively. The
scan width was set at 0.01 m/z and the scan time at 0.05 s. The peak
width settings for Q1 and Q3 were set at 0.7 mm.
Stock solutions, calibration standards and quality
controls (QCs)
Stock solutions of efavirenz and the internal standard were prepared from
the pure compounds in 100%methanol to obtain a final concentration of
1 mg/mL and refrigerated at 48C until use. A 10 mg/mL working stock of
efavirenz in breast milk was prepared by adding a predetermined volume
of efavirenz stock solution to drug-free breast milk, tumbled for 60 min
and used the same day. Nine calibration standards in the range of 50–
7500 ng/mL, together with low QC (LQC; 100 ng/mL), medium QC (MQC;
1500 ng/mL) and high QC (HQC; 6000 ng/mL), were prepared from separ-
ate working stocks by serial dilution with drug-free breast milk. Working
solution of efavirenz at concentrations equivalent to the QCs and
100 mg/mL of the internal standard were prepared in methanol:water
(50:50, v/v).
Dried milk spot calibration standard and QC preparation
Calibration standards andQCswere prepared by carefully spotting 30 mLof
spiked and well-mixed breast milk on each circle of Whatman 903 Protein
Saver cards. Spotted cards were left to dry at room temperature overnight
and stored with desiccant sachets in ziplock bags. QC samples for stability
testing were stored at room temperature, 2408C and 2808C.
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Sample pretreatment
In each case, the entire spot was removed using a 13 mm hole punch,
folded into a 7 mL screw cap tube and extracted with 1 mL of methanol
by tumbling for 30 min in the presence of 20 mL of the internal standard.
The extract was centrifuged at 4000 rpm for 5 min; supernatant was
transferred into a 5 mL tube and evaporated to dryness in a centrifugal
rotary vacuum evaporator (Thermo Electron Industries, Chateau Gontier,
France) operated at 408C. The residue was reconstituted in 500 mL of
mobile phase A and B (50:50, v/v) and aliquots were transferred into auto-
sampler vials. Each calibration standard level was prepared in duplicate
(n¼2) while the QCs were prepared in sextuplicate (n¼6).
Standard curve, accuracy and precision
Validation of the method was carried out as per FDA guidelines.25 Ten sep-
arate assays, each consisting of a zero blank (n¼2), nine calibration stan-
dards between 50 and 7500 ng/mL (n¼2) and QCs (n¼6) were run.
Calibration curves were constructed using a linear regression equation of
analyte/internal standard peak area ratios versus nominal concentrations
with a 1/concentration weighting. Accuracy was defined as percentage
deviation of measured concentration from the nominal value and precision
was defined as the percentage CV. Inter-individual precision was assessed
using a validation assay run by a different operator. At least 75% of calibra-
tion standards were required to have percentage deviation within+15%,
except for the lower limit of quantification (LLOQ), which is allowed to be
+20% of the nominal value. A percentage deviation and a CV within
+20% for LQC and within+15% for MQC and HQCwere set as acceptance
criteria for ≥67% of all QC samples and ≥50% of QCs at each level.25,26
Recovery, matrix effect and dilution integrity
Recovery was assessed by comparing peak area obtained from replicates
of each of the extracted QCs with the peak area obtained from the corre-
sponding solutions of efavirenz in mobile phase, as recommended by
Matuszewski et al.27 To evaluate matrix effect, six drug-free breast milk
samples from different donors were spotted onto Whatman 903 Protein
Saver cards and extracted as previously described. Each of the blank
extracts was spiked with the appropriate efavirenz working solution
(100, 1500 or 6000 ng/mL) to obtain final concentrations equivalent to
extracted dried breast milk spots at LQC, MQCor HQC. Identical concentra-
tions of unextracted samples were prepared by directly spiking working
solutions into mobile phase. Each concentration was evaluated in sextu-
plicate for each of the six breast milk samples. The overall recovery was
calculated as the ratio (expressed as a percentage) of the absolute
peak-area response of plasma samples spikedwith drug prior to extraction
to the peak area response of spikedmobile phase samples. The percentage
matrix effect was calculated as the ratio (expressed as a percentage) of
the peak area response of blank plasma extracts spiked post-extraction
to the peak areas of spiked mobile phase samples. A relative standard
deviation (RSD) of≤15%was set as the level of acceptance for both recov-
ery and matrix effect in line with the FDA and EMA guidelines.25,26 In add-
ition, we stipulated that mean recovery should be ,115% at any
concentration. Dilution integrity was evaluated to investigate the applic-
ability of the method to patient samples with efavirenz concentrations
above 7500 ng/mL. For this, 10 mg/mL efavirenz in breast milk was pre-
pared and 30 mL was spotted on each circle of Whatman 903 card,
dried and extracted as previously described. The extract was diluted 2×
and 4× using blank dried breast milk spots similarly extracted.
Stability and re-injection reproducibility
The stability of efavirenz in dried breast milk spots under different storage
and processing conditions was investigated. Short-term stability was eval-
uated by storing extracted QC samples at room temperature and in the
autosampler (48C) for 24 h and over the weekend (72 h). Short-term sta-
bility of processed patient samples (n¼10) from an accepted validation
assay run was also evaluated. For long-term stability at room tempera-
ture, 2408C and 2808C, QC samples were stored at these temperatures
for 6 months. The concentrations of the stored samples were determined
using calibration standards and QCs prepared with a freshly made efavir-
enz stock solution. To assess re-injection reproducibility in the event of
instrument interruption, an accepted validation assay run was re-injected
after 24 h in the autosampler.
Application in a pharmacokinetic study
Themethod was applied in a preliminary study to evaluate the breast milk
pharmacokinetic profile of efavirenz in HIV-positive nursing mothers
(n¼5) receiving regimens containing 600 mg efavirenz once daily.
Patients were recruited from Bishop Murray Medical Centre, Makurdi,
Nigeria and written informed consent was obtained prior to enrolment.
Mothers taking antimalarial, antituberculosis or other drugs known to
interact with efavirenzwere excluded. Breastmilk wasmanually expressed
by the mothers mid-feed into 5 mL tubes, 0.5, 1, 2, 4, 8, 12 and 24 h after
an observed evening dose of 600 mg efavirenz. To reflect real-life situa-
tions, patients took a standard local meal about 30 min before drug
administration. A 30 mL aliquot was immediately spotted on each circle
of Whatman 903 cards, dried and stored as previously described. Within
2 min of breast milk collection, whole blood samples were collected as
dried blood spots (DBS) after sterile skin cleaning and finger prick using a
2 mm safety lancet (BD, Oxford, Oxfordshire, UK). The first drop of blood
was discarded and subsequent blood drops were collected on Whatman
903 cards, dried and stored as described above. Samples were shipped at
room temperature to the Department of Molecular and Clinical
Pharmacology, University of Liverpool, Liverpool, UK for analysis.
Efavirenz in dried breast milk spots was quantified using the method
described above and efavirenz in DBS was quantified using a method
described elsewhere.28 Plasma efavirenz concentrations were estimated
using [DBS[EFV]/(12HCT)]×fbpp, where DBS[EFV] is efavirenz concentration
in DBS, HCT is the patient specific haematocrit and fbpp (0.995) is the frac-
tion of efavirenz bound to plasma protein.29 The study protocol and the
material transfer agreement were approved by the National Health
Research and Ethics Committee, Abuja and Obafemi Awolowo University
Teaching Hospitals Ethics and Research Committee, Ile-Ife, Nigeria.
Results
LC-MS/MS conditions
The total run time was 5 min and retention times of efavirenz and
the internal standard were 2.27 and 1.67 min, respectively.
Representative chromatograms are presented in Figure S1 (avail-
able as Supplementary data at JAC Online).
Linearity, accuracy and precision
The method was linear, accurate and precise in the range of 50–
7500 ng/mL. Mean regression coefficient (r2) was 0.9994 and the
average relative standard deviation of the internal standard
response was 3.7%. Accuracy (percentage bias) was between
95.2% and 102.5% and precision (CV) was between 1.05% and
9.53% (Table 1). These values arewithin bioanalytical method val-
idation acceptance criteria as per FDA and EMA guidelines.25,26
Recovery, matrix effect and dilution integrity
The average (CV) recoveries of efavirenz from dried breast milk
spots at LQC, MQC and HQC were 101.6% (7.40), 109.4% (2.58)
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and 108.2% (2.97), respectively. Matrix effect was within+15%
for each of the six different matrices, with an average (CV) of
9.05% (4.94), 8.15% (5.35) and 7.27% (4.17) at LQC, MQC and
HQC, respectively. The average efavirenz concentrations in the
10000 ng/mL dried breast milk spots diluted 2× and 4× were
10147 and 10893 ng/mL, representing 101.5% and 108.9%
dilution integrity, respectively.
Stability and re-injection reproducibility
Processed QC and incurred patient samples were stable at room
temperature and in the autosampler (48C) for 24 h and over the
weekend (72 h) with percentage deviations from nominal concen-
trations (for QC samples) or from the original assay results (for
patient samples) within+15%. The stability of efavirenz in dried
breast milk spots after storage for 6 months ranged from 92%
to 101% at room temperature, from 105% to 111% at 2408C
and from 110% to 113% at 2808C. Reinjection reproducibility
was demonstrated in a repeat analysis of an accepted validation
batch with all assay validation parameters within acceptable
limits.
Application in a pharmacokinetic study
The method was successfully applied to investigate the pharma-
cokinetics of efavirenz in human breast milk. Median (range) age
of mothers included was 29 years (25–34) and weight was 55 kg
(45–71). All fivemothers started an efavirenz-containing regimen
before delivery and samples were collected at steady-state,
146 days (108–194) after delivery. As shown in Figure 1(f), the
breast milk profile approximately paralleled the plasma profile.
Aswith the plasma, breastmilk concentrations also exhibited con-
siderable interindividual variability (Figure 1a–e). The mean (SD)
AUC, Cmax and Cmin were 59620 ng.h/mL (17440), 4527 ng/mL
(1767) and 1261 ng/mL (755.9), respectively, in breast milk.
Corresponding values in plasma were 74230 ng.h/mL (25610),
4711 ng/mL (1083) and 2571 ng/mL (1092), respectively
(Figure 1). Interestingly, breast milk efavirenz concentration
exceeded plasma concentration at some point during the dosing
interval in all five patients. Also, breast milk concentration was
predominantly higher than plasma concentration in patient
1. The average (range) milk-to-plasma (M/P) ratio over the dosing
interval was 0.78 (0.57–1.26). The M/P ratio was 0.83 at 4 h
post-dose.
Discussion
To our knowledge, this is the first description of a drug quantifica-
tion method in dried breast milk spots. Additionally, the full phar-
macokinetic profile of efavirenz in human breast milk has been
described for the first time. The simplicity, accuracy and precision
of the developed method will facilitate interlaboratory transfer.
The stability of efavirenz in dried breast milk spots at room tem-
perature will facilitate studies in settings with inadequate cold
storage facilities and shipping without the need for dry ice, thus
extending its utility in resource-limited settings. Other advantages
include patient acceptability, and reduction in perceived or actual
risks to the patient resulting from multiple sampling of large
volumes. The low sample volume required per assay may also
extend application of the method to pharmacokinetic studies in
animals in which adequate breast milk volumes may be difficult
to obtain because of low rate of milk production.10
As a result of the complexity of human breast milk, previously
described methods involve complicated extraction procedures
with a combination of liquid– liquid extraction and solid-phase
extraction for sample clean-up.11 Some authors have used
skimmed milk for validation, which has the potential for under-
estimating breast milk concentrations and hence the M/P ratio
of drugs that are highly bound to breast milk proteins and lipids.
The use of a dried matrix spot allows quantification of drug con-
centrations in whole milk because the cellulose material entraps
milk proteins and lipids on drying, allowing selective extraction of
analytes.
The ARVefavirenz, which is an essential component of first-line
regimens and frequently used by HIV-positive nursing mothers in
Table 1. Accuracy and precision for the quantification of efavirenz in dried breast milk spots
Concentration (ng/mL)
Inter-day Intra-day
mean SD precision (%CV) accuracy (%) mean SD precision (%CV) accuracy (%)
Calibration standards
50 50.4 2.78 5.51 100.8 51.0 3.48 6.83 101.9
100 98.2 3.04 3.09 98.2 98.6 1.54 1.56 98.7
200 198.9 10.05 5.05 99.5 193.5 2.92 1.51 96.8
500 500.8 11.59 2.31 100.2 495.7 5.19 1.05 99.1
1000 1017.7 41.40 4.07 101.8 1045.4 35.31 3.38 104.5
2000 2012.4 36.51 1.81 100.6 2013.8 27.55 1.37 100.7
3500 3473.9 23.90 0.69 99.3 3464.4 27.00 0.78 99.0
5000 4961.2 75.80 1.53 99.2 4918.8 23.01 0.47 98.4
7500 7539.5 87.62 1.16 100.5 7574.4 83.04 1.10 100.0
QC
LQC (100) 99.5 9.48 9.53 99.5 101.7 6.29 6.19 101.7
MQC (1500) 1427.7 72.73 5.09 95.2 1492.2 40.98 2.75 99.5
HQC (6000) 6125.1 313.10 5.11 102.1 6087.1 330.04 5.37 102.5
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developing countries, is not licensed for use in children,3 months
old or,3.5 kg30 because optimal dosing and safety have not been
fully evaluated in this age group. In the first report of its excretion
in breast milk by Schneider et al.,12 single-point breast milk and
plasma samples were collected 3–4 h post-dose and the M/P
ratio was 0.54, compared with the M/P ratio of 0.83 at 4 h post-
dose in the present study. This difference may be due to the
use of skimmed milk instead of whole milk in the former study,
resulting in underestimation of the breast milk concentrations of
efavirenz, which in plasma is 99.5% protein bound. In addition,
changes in milk production, composition and infant feeding pat-
ternsmay cause variations in theM/P ratio during the dosing inter-
val,31 making single-point estimates inaccurate and often
misleading.6 Breast milk is more lipophilic than plasma; efavirenz
may preferentially partition into this compartment and accumu-
late after maternal dose before the next infant feed. In fact, we
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Figure 1. Concentration–time profiles of efavirenz in breast milk and plasma of five HIV-positive nursing mothers (a–e) taking regimens containing
600 mg of efavirenz once daily. The mean (SD) of all five patients is shown in (f). The mean (range) M/P ratio over the dosing interval was 0.78
(0.57–1.26).
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observed intra- and interindividual variations in the M/P ratio dur-
ing the dosing interval in the present study. In addition to the fac-
tors highlighted above, genetic factors may also play some role.32
Using our method, M/P ratio ranged from 0.57 to 1.26 with an
average of 0.78 over the 24 h dosing interval.
Uncertainties surrounding the use of many drugs during lacta-
tion may result in suboptimal adherence to essential pharmaco-
therapy or premature recourse to formula feeding by nursing
mothers. In the context of HIV/AIDS, this will not be affordable,
feasible, acceptable, sustainable or safe for the majority of the
world’s HIV-positive women living in resource-limited countries.
The availability of validated bioanalytical methods for the quanti-
fication of drugs in human breast milk is an important step
towards resolving some of these uncertainties and clarifying the
pharmacokinetics of drugs in this compartment. The dried milk
spot method presented here is simple, accurate and precise and
further studies to investigate applications for other drugs that
may be used during lactation are warranted. A useful approach
will be to modify methods already validated for the drug of inter-
est in other matrices. Additional validation steps to establish a
suitable extraction procedure, optimal recovery and drug stability
in dried breast milk spot will be needed as per FDA guidelines.25
In the present study, a potential limitation is that a cross-
validation comparing the dried breast milk spot method with
the traditional liquid breast milk method was not conducted.
Also, unlike DBS, which can be collected directly from patients
after a finger prick, the dried breastmilkmethod relies on accurate
pipetting from expressed breast milk and spotting on sample col-
lection cards. It is also essential that spotting be limited to the
marked sample collection areas on the cards since breast milk is
colourless.
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